Is there a difference in the long term safety of tenofovir disoproxil fumarate (TDF) versus tenofovir alafenamide (TAF) used for HIV pre-exposure prophylaxis?
my part is to answer question 3 and 4 (which is below):
- How will you get your study participants? Recruit from 2019 to 2021, or until 100,000 initial participants 5 cities, 20,000 each San Francisco Houston Atlanta NYC Seattle
- For trials —How will you randomize? Why? Randomly assigned TAF vs TDF, ensure baseline population demographics are comparable Double blind, randomized, parallel assignment.
Sample Solution